Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naloxegol - AstraZeneca/Nektar Therapeutics

Drug Profile

Naloxegol - AstraZeneca/Nektar Therapeutics

Alternative Names: AZ13337019 oxalate; MOVANTIK; Movantik; Moventig; Naloxegol oxalate; NKTR-118; NKTR-118 oxalate; PEG-naloxol; Pegylated naloxol

Latest Information Update: 19 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Daiichi Sankyo Company; Knight Therapeutics; Nektar Therapeutics; Temple University
  • Class Gastrokinetics; Laxatives; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II Gastroparesis

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Constipation(In volunteers) in Germany (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2018 Nektar Therapeutics has patent protection for naloxegol in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top